{
    "clinical_study": {
        "@rank": "164661", 
        "arm_group": [
            {
                "arm_group_label": "dalteparin 5000IU s.c.", 
                "arm_group_type": "Active Comparator", 
                "description": "5000IU dalteparin s.c. injected the evening before cemented total hip arthroplasty"
            }, 
            {
                "arm_group_label": "saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Syringes of Saline with the same volume as in the dalteparin injections are injected the evenings before total hip arthroplasty. Dalteparin 5000IU are injected 6 hours after surgery and the concomitant 33 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if there are differences in clinical events, i.e\n      bleeding with associated morbidity, if thromboprophylaxis with LMWH (Low Molecular Weight\n      Heparin) is initiated before or after surgery."
        }, 
        "brief_title": "Preoperative Versus Postoperative Start With Thromboprophylaxis in THA (Total Hip Arthroplasty)", 
        "completion_date": {
            "#text": "April 2009", 
            "@type": "Actual"
        }, 
        "condition": [
            "Arthritis of the Hip", 
            "Transfusion Related Complications", 
            "Infection", 
            "Wound Discharge"
        ], 
        "condition_browse": {
            "mesh_term": "Arthritis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        -patients 50 years or older undergoing cemented total hip arthroplasty for primary\n        osteoarthritis\n\n        Exclusion Criteria:\n\n          -  allergy to Low-Molecular-Weight -Heparin\n\n          -  bleeding disorders\n\n          -  renal failure\n\n          -  hepatic disease\n\n          -  active treatment for malignancy\n\n          -  history of deep venous thrombosis or pulmonary embolism\n\n          -  major operations,trauma,stroke or cardiac infarction the last 3 months before\n             surgery."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01714297", 
            "org_study_id": "REK S\u00f8r-\u00f8st s-08012d"
        }, 
        "intervention": {
            "arm_group_label": [
                "dalteparin 5000IU s.c.", 
                "saline"
            ], 
            "description": "All patients receive injections with either 5000IU dalteparin or saline in the same volume the evening before surgery. All patients receive 5000IU dalteparin 6 hours after surgery and every day from day 2 until day 35.", 
            "intervention_name": "dalteparin 5000 IU s.c.", 
            "intervention_type": "Drug", 
            "other_name": "Fragmin"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dalteparin", 
                "Heparin, Low-Molecular-Weight"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "cemented total hip arthroplasty", 
            "blood loss", 
            "wound discharge", 
            "thromboprophylaxis", 
            "biomarkers"
        ], 
        "lastchanged_date": "December 7, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Sandvika", 
                    "country": "Norway", 
                    "state": "Gjettum", 
                    "zip": "1346"
                }, 
                "name": "Martina Hansen's Hospital"
            }
        }, 
        "location_countries": {
            "country": "Norway"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective Randomized, Double Blind Study to Evaluate Safety and Effect With Pre Versus Postoperative Start of Thromboprophylaxis With Dalteparin", 
        "overall_official": {
            "affiliation": "Oslo University Hospital", 
            "last_name": "Olav Reikeras, MD, Phd", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Norway: Directorate of Health", 
                "Norway: Regional Ethics Commitee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "measured blood loss during surgery and in wound drains", 
            "measure": "total blood loss", 
            "safety_issue": "Yes", 
            "time_frame": "during and after surgery"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01714297"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Martina Hansen's Hospital", 
            "investigator_full_name": "P\u00e5l Borgen, MD", 
            "investigator_title": "MD.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": {
            "PMID": "22476844", 
            "citation": "Borgen PO, Dahl OE, Reiker\u00e5s O. Blood loss in cemented THA is not reduced with postoperative versus preoperative start of thromboprophylaxis. Clin Orthop Relat Res. 2012 Sep;470(9):2591-8. doi: 10.1007/s11999-012-2320-9. Epub 2012 Apr 3."
        }, 
        "secondary_outcome": [
            {
                "description": "number of units packed red blood cells", 
                "measure": "transfusion requirements", 
                "safety_issue": "Yes", 
                "time_frame": "during and after surgery"
            }, 
            {
                "description": "excessive bleeding, wound hematoma, wound secretion, other bleeding events", 
                "measure": "incidence of bleeding events", 
                "safety_issue": "Yes", 
                "time_frame": "during and after surgery"
            }, 
            {
                "description": "all other complications related to surgery", 
                "measure": "other complications", 
                "safety_issue": "Yes", 
                "time_frame": "during and after surgery"
            }
        ], 
        "source": "Martina Hansen's Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Oslo University Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Martina Hansen's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}